0000950170-24-077029.txt : 20240624
0000950170-24-077029.hdr.sgml : 20240624
20240624204102
ACCESSION NUMBER: 0000950170-24-077029
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240621
FILED AS OF DATE: 20240624
DATE AS OF CHANGE: 20240624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HIGH SUSANNA GATTI
CENTRAL INDEX KEY: 0001691005
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 241065981
MAIL ADDRESS:
STREET 1: 75 LORIMER ROAD
CITY: BELMONT
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
ownership.xml
4
X0508
4
2024-06-21
0001818794
Dyne Therapeutics, Inc.
DYN
0001691005
HIGH SUSANNA GATTI
1560 TRAPELO ROAD
WALTHAM
MA
02451
false
true
false
false
Chief Operating Officer
true
Common Stock
2024-06-21
4
M
false
29787
5.54
A
178579
D
Common Stock
2024-06-21
4
S
false
29787
35.01
D
148792
D
Common Stock
2024-06-24
4
M
false
10163
5.54
A
158955
D
Common Stock
2024-06-24
4
S
false
10163
35.33
D
148792
D
Stock option (right to buy)
5.54
2024-06-21
4
M
false
29787
0
D
2030-07-30
Common Stock
29787
70699
D
Stock option (right to buy)
5.54
2024-06-24
4
M
false
10163
0.00
D
2030-07-30
Common Stock
10163
60536
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.60, inclusive.
Includes 134,629 unvested RSUs.
The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter.
/s/ Richard Scalzo, Attorney-in-Fact
2024-06-24